On December 3, 2024, Eric Schwartz, Executive Vice President, Chief Legal Officer & Secretary of Integra Lifesciences Holdings Corp (IART, Financial), sold 4,070 shares of the company. Following this transaction, the insider now owns 59,511 shares of the company. The details of this transaction can be found in the SEC Filing.
Integra Lifesciences Holdings Corp (IART) is a global leader in medical technology, offering innovative solutions in neurosurgery, reconstructive, and general surgery. The company is known for its comprehensive portfolio of products that are used in hospitals, surgery centers, and physician offices.
The insider transaction history for Integra Lifesciences Holdings Corp shows that there have been 2 insider buys and 4 insider sells over the past year. This recent sale by Eric Schwartz is part of the broader trend of insider selling within the company.
On the day of the transaction, shares of Integra Lifesciences Holdings Corp were trading at $24.6, giving the stock a market cap of $1.860 billion. The stock's GF Value is estimated at $49.20, resulting in a price-to-GF-Value ratio of 0.5. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
